A dermatologist prescribed a topical solution with 7% minoxidil, 0.1% finasteride, and 0.015% tretinoin from Medrock pharmacy. The user is asking if anyone has tried it and if it contains alcohol.
Significant hair regrowth was achieved using a topical combination of 0.3% finasteride and 6% minoxidil, with weekly dermastamping and ketoconazole shampoo, without side effects. Others suggested additional treatments like red light therapy and PRP.
Minoxidil and finasteride topical solutions may last longer than their labeled best before date, with users experiencing varying side effects and effectiveness over time. Some users report reduced side effects and increased hair loss towards the end of the second month of use.
Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.
The user left their 2.5 mg pills at home and is considering using 5% topical minoxidil as a substitute. They also inquire about where to obtain over-the-counter minoxidil pills.
The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.
RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.
The user has been using finasteride for hair loss and is considering adding RU58841. They ask about RU58841's effectiveness, potential heart side effects, duration of action, dosage increase over time, transitioning to GT20029, and where to find the liquid form.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
The user discusses using Follics FR5, FR10, and FR15, which combine Minoxidil, Adenosine, Procapil, Azelaic acid, and Procyanidin B2, to address hair loss. They have previously used Minoxidil, Finasteride, and Dutasteride with varying success.
The user shared progress pictures showing significant hair growth after using minoxidil, dutasteride, and ketoconazole shampoo. They reported seeing results in 1.5-2 months and discussed the effectiveness of oral treatments over topical ones.
The conversation is about a user seeking advice on adding GHK-Cu to RU58841 for hair loss treatment, while already using oral minoxidil, dutasteride, ketoconazole shampoo, and considering LLLT. They are unsure about the concentration and carrier solution for GHK-Cu.
The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.
A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.
A clinical trial for Verteporfin as a hair loss treatment, and the potential for greater progress in treatments for hair loss in the future. Common treatments such as Minoxidil, Finasteride and RU58841 were discussed.
Exploring the potential of using Verteporfin to grow follicles in combination with microneedling, as well as the cost of administering a single injection and the possibility of combining it with minoxidil.
The conversation discusses hair loss treatment progress using finasteride for 5 months and a topical solution with 0.1% minoxidil and 7% RU58841 for 11 months, with plans to switch to a stronger topical solution with 0.25% minoxidil, 7% RU58841, and tretinoin. Opinions on improvement are mixed.
PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
A 31-year-old man from India is starting a hair loss treatment routine using finasteride, minoxidil, ketoconazole shampoo, and supplements for vitamin deficiencies. He is considering switching to oral minoxidil and possibly using Redensyl serum, while also exploring the effectiveness of dutasteride compared to finasteride.
The conversation is about the effectiveness and safety of a hair loss treatment called Pyri, with users discussing its availability and comparing it to other treatments like RU58841, fluridil, and alfatradiol. Some users are waiting for FDA approval before using Pyri, while others share their positive experiences with RU58841 and suggest additional treatments with minimal side effects.
The conversation discusses using Morr F Aqua, an alcohol-free version of Minoxidil, for hair loss, particularly for someone with dandruff issues. The user is considering if this product is suitable for their condition.
Minoxidil, derma stamp, and Nizoral shampoo are being considered to maintain hair until finasteride can be used. The user is contemplating adding RU58841 or KX-826.
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
Skin, Hair, and Nails by Pharmekal was withdrawn from the market. Users discuss alternative supplements and treatments like Minoxidil, finasteride, and RU58841.
The conversation discusses experiences with topical dutasteride for hair loss, comparing formulations from FUEClinic, MinoxidilMax, and Strut. Users share their results and side effects, with some preferring topical over oral treatments to minimize systemic absorption.
The conversation is about difficulty finding a reputable source for Latanoprost or Bimatoprost in pure powder form or high concentrations for hair loss treatment, with only low concentration solutions being readily available.
The user is considering switching from topical finasteride to oral finasteride and is seeking advice on whether to transition directly or use both forms temporarily. They express concern about potential side effects.